Inactive Instrument

Zogenix, Inc.

ZGNX

US98978L2043

Zogenix Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter 2020

January 11, 2021 at 08:00 am

Zogenix provided preliminary unaudited earnings guidance for the fourth quarter 2020. For the quarter, the company expects total FINTEPLA net product sales to be approximately $8.1 million.

Latest news about Zogenix, Inc.

Pulmocide Announces Expansion of Management Team	23-06-08	CI
U.S. FDA approves UCB's drug for rare childhood epilepsy	22-03-28	RE
Zogenix Completes $1.9 Billion Buyout by UCB; Shares Delisted From Nasdaq	22-03-07	MT
UCB Closes Zogenix Acquisition for Nearly $1.9 Billion	22-03-07	MT
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Composite Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Pharmaceuticals Select Industry Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P TMI Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Global BMI Index	22-03-07	CI
UCB BioSciences, Inc. completed the acquisition of Zogenix, Inc..	22-03-03	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Biotechnology Index	22-03-01	CI
Northland Downgrades Zogenix to Market Perform From Outperform, Lifts Price Target to $27 From $26	22-02-28	MT
Zogenix Q4 Loss Narrows, Revenue Increases	22-02-28	MT
Zogenix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-28	CI
Zogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Earnings Flash (ZGNX) ZOGENIX Posts Q4 Revenue $26.6M	22-02-28	MT
Health Care Stocks Floundering Late in Wednesday Trading	22-01-19	MT
JMP Securities Downgrades Zogenix to Market Perform From Market Outperform	22-01-19	MT
Top Midday Gainers	22-01-19	MT
Health Care Stocks Moderately Higher Wednesday Afternoon	22-01-19	MT
Needham & Co Downgrades Zogenix to Hold From Buy	22-01-19	MT
Guggenheim Downgrades Zogenix to Neutral From Buy, Adjusts Price Target to $28 From $35	22-01-19	MT
William Blair Downgrades Zogenix to Market Perform From Outperform	22-01-19	MT
Zogenix Agrees to $1.9 Billion Takeover by UCB; Shares Surge	22-01-19	MT
Wall Street Set for Recovery After Bond Yield-Induced Sell-Off	22-01-19	MT
Health Care Stocks Edge Higher Premarket Wednesday	22-01-19	MT

Zogenix Inc is a United States-based biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
BIOGEN INC.	-12.88%	32.82B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
INCYTE CORPORATION	-5.78%	13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B

Biopharmaceuticals